Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

The research, published in The New England Journal of Medicine, showed that tirzepatide also helped people reduce more belly fat, with an average waistline drop of 7.2 inches, compared to 5.1 ...

CHICAGO — ­New clinical trial results on the diabetes and obesity drug tirzepatide have doctors buzzing about its potential to treat heart failure, keep weight off and prevent type 2 diabetes ...

Researchers conducted a post hoc analysis of the SURMOUNT-1 trial to assess the effect of tirzepatide on kidney function in prediabetes with obesity or overweight.

Studies were included if they were clinical- or randomized controlled trials investigating the performance of Tirzepatide against insulin in any of the following outcomes – Body weight, fasting ...

Tirzepatide dose escalation is slower in real-world settings than clinical trials among individuals without type 2 diabetes (T2D) but with multiple comorbidities, according to study results published ...

Tirzepatide is a medication focused on reducing the risk of developing Type 2 diabetes by 94 percent in prediabetic adults in a clinical trial according to Eli Lilly. Tirzepatide was evaluated in ...

The company acknowledged there was a mismatch between dosing of tirzepatide in clinical practice and the clinical trials, but noted the same issue applies to all comparator trials. The clinical ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference. And ...

Tirzepatide dose escalation is slower in real-world settings than clinical trials among individuals without type 2 diabetes (T2D) but with multiple comorbidities, according to study results ...